- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05647564
치료 내성의 PET/CT 특성화
MCRPC에서 AR 표적 요법의 치료 내성에 대한 PET/CT 특성화
This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are either scheduled to start a second-generation androgen receptor (AR) targeted therapy (such as enzalutamide, abiraterone, or apalutamide) or are already being treated with one. Participants can expect to be in the study for at least 9 months, and up to 2 years.
연구 개요
상태
정황
상세 설명
There are two groups, or cohorts, in this study. Participants are assigned to Cohort A if they have advanced prostate cancer and are scheduled to start a second-generation AR-targeted therapy (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed radiotherapy (e.g. Lu177-PSMA radio-ligand therapy. Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels.
There are two medical imaging scans that will be done for research purposes in this study. One is called 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and the other is prostate-specific membrane antigen positron emission tomography (PSMA PET). These scans are done simultaneously with computed tomography (CT) scanning. Participants will be scheduled to have 6 scans, 3 FDG PET/CT scans and 3 PSMA PET/CT scans.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Cancer Connect
- 전화번호: 800-622-8922
- 이메일: clinicaltrials@cancer.wisc.edu
연구 장소
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53705
- 모병
- University of Wisconsin
-
연락하다:
- Cancer Connect
- 전화번호: 800-622-8922
- 이메일: clinicaltrials@cancer.wisc.edu
-
수석 연구원:
- John Floberg, MD, PhD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically proven adenocarcinoma of the prostate.
- At least 1 radiographic metastases as seen on conventional CT imaging or bone scan
- Progressive prostate cancer as evident by at least two separate increase in PSA over nadir, and absolute PSA value at least 2 ng/ml (INTRINSIC RESISTANCE COHORT, ARSI patients ONLY)
- Patients must be candidate for a second-generation androgen receptor (AR) inhibitor (e.g. enzalutamide, abiraterone, darolutamide, apalutamide), or Lu177-PSMA radioligand therapy (INTRINSIC RESISTANCE COHORT ONLY)
- Men of age >18 years.
- Patients must be able to comply with all study procedures, including having both the ability and willingness to lie flat for ≥ 30 minutes during imaging
- Patients must be informed of the exploratory nature of the study and its potential risks, and must sign IRB-approved consent form indicating such understanding.
- Life-expectancy at least 12 months
- Patients currently receiving a second-generation androgen receptor (AR) inhibitor (e.g. enzalutamide, abiraterone, darolutamide, apalutamide) and must have had 1) PSA decline on treatment and 2) now have PSA increase over nadir while still on treatment (patients must be registered within 12 weeks of first documented PSA increase) (ACQUIRED RESISTANCE COHORT ONLY)
Exclusion Criteria:
- Must not have uncontrolled diabetes (fasting blood sugar > 200 mg/dL or inability to safely hold diabetes medication or fast 6 hours prior to FDG PET scan)
- Prior treatment with second-generation AR inhibitor for prostate cancer in the metastatic disease setting (prior second-generation AR inhibitor in the neoadjuvant or adjuvant setting is permitted unless patient developed progression while on treatment) (INTRINSIC RESISTANCE COHORT, AR-INHIBITOR GROUP ONLY)
- Pain or clinical symptoms from metastatic prostate cancer requiring opioid analgesics
- Known neuro-endocrine prostate cancer
- Prior radioisotope therapy for castration-resistant prostate cancer
- To avoid the possibility of unintended coercion, vulnerable populations such as incarcerated subjects, subjects unable to provide their own informed consent and non-English speaking patients will not be considered
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: Intrinsic Resistance Cohort (Cohort A)
Participants assigned to Cohort A have advanced prostate cancer and are scheduled to start a second-generation AR-targeted (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed (e.g. Lu177-PSMA) therapies . |
Imaging scan Imaging scan |
|
다른: Acquired Resistance Cohort (Cohort B)
Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels. |
Imaging scan Imaging scan |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Characterize intrinsic resistance based on FDG and PSMA PET through change in individual lesion update levels.
기간: Baseline to 12 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which less activity is better. |
Baseline to 12 weeks
|
|
Characterize change in intrinsic resistance based on FDG and PSMA PET.
기간: Baseline to 12 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better. |
Baseline to 12 weeks
|
|
Characterize change in intrinsic resistance based on FDG and PSMA PET.
기간: 12 weeks to 36 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better. |
12 weeks to 36 weeks
|
|
Characterize change in intrinsic resistance based on FDG and PSMA PET.
기간: Baseline to 36 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better. |
Baseline to 36 weeks
|
|
Characterize acquired resistance at the time of progression
기간: Baseline to 36 weeks
|
Percentage and absolute changes in individual lesion update levels (ΔiSUVtotal) will be calculated. |
Baseline to 36 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to PSA progression
기간: Baseline to 36 weeks
|
Analysis will be conducted to evaluate whether changes in lesion uptake values predict time to PSA progression. PSA progression will be 25% increase and >2 ng/mL above PSA nadir |
Baseline to 36 weeks
|
|
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to radiographic progression
기간: Baseline to 36 weeks
|
Analysis will be conducted to evaluate whether changes in lesion uptake values predict time to radiographic progression. Time to radiographic progression will be defined as the number of days to confirmed radiographic progression using Prostate Cancer WorkingGroup 3 (PCWG3) criteria. |
Baseline to 36 weeks
|
|
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time duration on treatment
기간: Up to 36 weeks
|
Analysis will be conducted to evaluate whether changes in lesion uptake values predict duration of treatment. Duration of treatment will be defined as the time from treatment start, to treatment discontinuation (and reason for discontinuation) using PCWG3 criteria. |
Up to 36 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Glenn Liu, MD, University of Wisconsin, Madison
- 수석 연구원: Robert Jeraj, PhD, University of Wisconsin, Madison
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2022-0910
- A534260 (기타 식별자: UW Madison)
- 2022-0910 (기타 식별자: UW Madison)
- SMPH/MEDICINE/HEM-ONC (기타 식별자: UW Madison)
- NCI-2022-09580 (레지스트리 식별자: NCI)
- Protocol Version 8/1/2026 (기타 식별자: UW Madison)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .